Xintela publishes results from glioblastoma antibody study
Lund, Sweden, March 12, 2021 – Xintela announces that the results of the company’s preclinical glioblastoma study with function-blocking antibodies have today been published in the renowned international scientific journal Cancers. The publication shows, among other things, that antibodies directed to the company’s target molecule integrin 101 significantly reduce the growth of the aggressive and […]
Year-end report 1 Jan – 31 Dec 2020
Summary of the year-end report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Twelve months (1 Jan 2020-31 Dec 2020) Net sales amounted to TSEK 0 (38). Loss before tax totalled TSEK 50,257 (loss: 43,530). Loss per share* was SEK 0.68 (loss: 1.10). At 31 December 2020, the equity/assets ratio** […]
Newsletter December 2020
Dear shareholders, It has been an unusual year that was dominated by COVID-19 and we have had to adapt our business to the prevailing pandemic. Thanks to the fantastic effort by our team and strict procedures, we have nonetheless been able continue our operations safely and can now say that 2020 was a very successful […]
Xintela receives Notice of Allowance from USPTO for the treatment of brain tumors
Lund, Sweden, January 7, 2021 – Xintela today announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application covering targeted antibody treatment of tumors of the central nervous system (CNS). Xintela’s patent application 15/550,837 in the USA protects the use of the target molecule integrin […]
Xintela submits manufacturing license application
Lund, Sweden, 21 December 2020 – Xintela announces today that the company has submitted its application to the Swedish Medical Products Agency for a license to produce cell therapy products, also known as Advanced Therapy Medicinal Products (ATMPs), for clinical studies. Xintela has developed and patented the stem cell product platform XSTEM® and built its […]
Xintela recruits Jeffrey Abbey to Targinta
Lund, Sweden, 14 December 2020 -Xintela AB (publ) announces that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Mr. Abbey has more than 20 years of experience in the biopharmaceutical industry and has spent much of his career focused on the development of […]
Arbitral award rendered in favour of Xintela in dispute with former underwriters
Lund, Sweden, 4 December 2020 -Xintela AB (publ) announces that the arbitral tribunal today has rendered an arbitral award in the dispute between Xintela and four former underwriters. The arbitral award dismisses the claim for payment brought by the underwriters against Xintela in its entirety. The arbitral award concerns the dispute that arose in connection […]
Xintela Board recommends Maarten de Château as new Board member
Lund, Sweden, 3 December 2020 -Xintela AB (publ) announces that Maarten de Château has accepted an invitation to join the Xintela Board of Directors. The Xintela Board will recommend that shareholders formally appoint Maarten at the next shareholders meeting. In the meantime, Maarten will be adjoined to future Board meetings. Maarten de Château is currently […]
Xintela publishes interim report for the third quarter of 2020
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First nine months of the year (1 Jan 2020-30 Sep 2020)· Net sales amounted to TSEK 0 (3).· Loss before tax totalled TSEK 24,922 (loss: 28,081).· Loss per share* was SEK 0.43 (loss: 0.71).· At 30 September 2020, […]
Xintela Board recommends Lars Hedbys as new Board member
Lund, Sweden, 12 November 2020 -Xintela AB (publ) announces that Lars Hedbys has accepted an invitation to join the Xintela Board of Directors. The Xintela Board will recommend that shareholders formally appoint Lars at the next shareholders meeting. In the meantime, Lars will be adjoined to future Board meetings. Lars Hedbys (born 1957) has significant […]
